{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T23:31:18Z","timestamp":1782603078874,"version":"3.54.5"},"reference-count":78,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,12,14]],"date-time":"2020-12-14T00:00:00Z","timestamp":1607904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Malignant pleural mesothelioma (MPM) is strongly associated with occupational or environmental asbestos exposure and arises from neoplastic transformation of mesothelial cells in the pleural cavity. The only standard initial treatment for unresectable MPM is combination chemotherapy with cisplatin (CDDP) and pemetrexed (PEM). Further, CDDP\/PEM is the only approved regimen with evidence of prolonged overall survival (OS), although the median OS for patients treated with this regimen is only 12 months after diagnosis. Thus, the development of new therapeutic strategies has been investigated for approximately 20 years. In contrast to recent advances in personalized lung cancer therapies, diagnostic and prognostic biomarker research has just started in mesothelioma. Epigenetic alterations include DNA methylation, histone modifications, and other chromatin-remodeling events. These processes are involved in numerous cellular processes including differentiation, development, and tumorigenesis. Epigenetic modifications play an important role in gene expression and regulation related to malignant MPM phenotypes and histological subtypes. An immune checkpoint PD-1 inhibitor, nivolumab, was approved as second-line therapy for patients who had failed initial chemotherapy, based on the results of the MERIT study. Various clinical immunotherapy trials are ongoing in patients with advanced MPM. In this review, we describe recent knowledge on epigenetic alterations, which might identify candidate therapeutic targets and immunotherapeutic regimens under development for MPM.<\/jats:p>","DOI":"10.3389\/fonc.2020.554570","type":"journal-article","created":{"date-parts":[[2021,1,10]],"date-time":"2021-01-10T14:17:39Z","timestamp":1610288259000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Epigenetic Alterations and Biomarkers for Immune Checkpoint Inhibitors\u2013Current Standards and Future Perspectives in Malignant Pleural Mesothelioma Treatment"],"prefix":"10.3389","volume":"10","author":[{"given":"Yoshie","family":"Yoshikawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kozo","family":"Kuribayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Minami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Ohmuraya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kijima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,12,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1080\/17476348.2019.1679119","article-title":"Types of surgery post-neoadjuvant chemotherapy for pleural mesothelioma","volume":"13","author":"Kuribayashi","year":"2019","journal-title":"Expert Rev Respir Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/crj.12778","article-title":"Global trends in mortality from malignant mesothelioma: Analysis of WHO mortality database (1994-2013)","volume":"12","author":"Abdel-Rahman","year":"2018","journal-title":"Clin Respir J"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30100-1","article-title":"Novel therapies for malignant pleural mesothelioma","volume":"19","author":"Scherpereel","year":"2018","journal-title":"Lancet Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S0140-6736(05)67025-0","article-title":"Malignant mesothelioma","volume":"366","author":"Robinson","year":"2005","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat Genet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-1008","article-title":"Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma","volume":"75","author":"Guo","year":"2015","journal-title":"Cancer Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0804","article-title":"Integrative Molecular Characterization of Malignant Pleural Mesothelioma","volume":"8","author":"Hmeljak","year":"2018","journal-title":"Cancer Discov"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1612074113","article-title":"High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma","volume":"113","author":"Yoshikawa","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.10.001","article-title":"Neoantigenic Potential of Complex Chromosomal Rearrangements in Mesothelioma","volume":"14","author":"Mansfield","year":"2019","journal-title":"J Thorac Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2017.06.06","article-title":"Targeting the epigenome in malignant pleural mesothelioma","volume":"6","author":"McLoughlin","year":"2017","journal-title":"Transl Lung Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1038\/s41467-019-09307-6","article-title":"Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications","volume":"10","author":"Blum","year":"2019","journal-title":"Nat Commun"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3947","article-title":"Loss of BAP1 function leads to EZH2-dependent transformation","volume":"21","author":"LaFave","year":"2015","journal-title":"Nat Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29015","article-title":"Biallelic germline and somatic mutations in malignant mesothelioma: multiple mutations in transcription regulators including mSWI\/SNF genes","volume":"136","author":"Yoshikawa","year":"2015","journal-title":"Int J Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00650","article-title":"MicroRNAs for the Diagnosis and Management of Malignant Pleural Mesothelioma: A Literature Review","volume":"8","author":"Lo Russo","year":"2018","journal-title":"Front Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00445","article-title":"Circulating Epigenetic Biomarkers in Malignant Pleural Mesothelioma: State of the Art and critical Evaluation","volume":"10","author":"Ferrari","year":"2020","journal-title":"Front Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1080\/10937404.2016.1193361","article-title":"Five years update on relationships between malignant pleural mesothelioma and exposure to asbestos and other elongated mineral particles","volume":"19","author":"Andujar","year":"2016","journal-title":"J Toxicol Environ Health B Crit Rev"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2007.10.026","article-title":"Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma","volume":"135","author":"Anraku","year":"2008","journal-title":"J Thorac Cardiovasc Surg"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-010-0881-6","article-title":"CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection","volume":"59","author":"Yamada","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201506-315LE","article-title":"Spontaneous Regression of Malignant Pleural Mesothelioma in a Patient with New-Onset Inflammatory Arthropathy","volume":"12","author":"Moser","year":"2015","journal-title":"Ann Am Thorac Soc"},{"key":"B20","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/s0169-5002(00)00217-8","article-title":"Localised spontaneous regression in mesothelioma \u2013 possible immunological mechanism","volume":"32","author":"Robinson","year":"2001","journal-title":"Lung Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2017.04.01","article-title":"Immunotherapy and radiation therapy for malignant pleural mesothelioma","volume":"6","author":"Alley","year":"2017","journal-title":"Transl Lung Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201608-1755CI","article-title":"Checkpoint Blockade in Lung Cancer and Mesothelioma","volume":"196","author":"Lievense","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.09.009","article-title":"A multicentre randomised phase III trial comparing pembrolizumab vs single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial","volume":"22","author":"Popat","year":"2020","journal-title":"Ann Oncol"},{"key":"B25","article-title":"Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas","volume":"9","author":"Illei","year":"2003","journal-title":"Clin Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2008.08.014","article-title":"Functional inactivation of NF2\/merlin in human mesothelioma","volume":"64","author":"Thurneysen","year":"2009","journal-title":"Lung Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1827.2011.02666.x","article-title":"Inactivation of Merlin in malignant mesothelioma cells and the Hippo signaling cascade dysregulation","volume":"61","author":"Sekido","year":"2011","journal-title":"Pathol Int"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00005.2014","article-title":"The biology of YAP\/TAZ: hippo signaling and beyond","volume":"94","author":"Piccolo","year":"2014","journal-title":"Physiol Rev"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.01578-08","article-title":"Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling","volume":"29","author":"Lopez-Lago","year":"2009","journal-title":"Mol Cell Biol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000471","article-title":"High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma","volume":"10","author":"Nasu","year":"2015","journal-title":"J Thorac Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3459","article-title":"BAP1 and cancer","volume":"13","author":"Carbone","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/ng.912","article-title":"Germline BAP1 mutations predispose to malignant mesothelioma","volume":"43","author":"Testa","year":"2011","journal-title":"Nat Genet"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.17.00073","article-title":"Landscape of microsatellite instability across 39 cancer types","volume":"1","author":"Bonneville","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-019-02275-9","article-title":"Analysis of mismatch repair (MMR) proteins expression in a series of malignant pleural mesothelioma (MPM) patients","volume":"22","author":"Cedres","year":"2020","journal-title":"Clin Transl Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/0022-2836(87)90689-9","article-title":"CpG islands in vertebrate genomes","volume":"196","author":"Gardiner-Garden","year":"1987","journal-title":"J Mol Biol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a019133","article-title":"DNA methylation in mammals","volume":"6","author":"Li","year":"2014","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a019505","article-title":"Epigenetic Determinants of Cancer","volume":"8","author":"Baylin","year":"2016","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-1595","article-title":"Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma","volume":"69","author":"Goto","year":"2009","journal-title":"Cancer Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-0190","article-title":"Integrated profiling reveals a global correlation between epigenetic and genetic alterations in mesothelioma","volume":"70","author":"Christensen","year":"2010","journal-title":"Cancer Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.10.163","article-title":"Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects","volume":"14","author":"Guarrera","year":"2019","journal-title":"J Thorac Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19970601)79:11<2237::AID-CNCR23>3.0.CO;2-W","article-title":"Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer and Leukemia Group B","volume":"79","author":"Yogelzang","year":"1997","journal-title":"Cancer"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/38664","article-title":"Histone acetylation in chromatin structure and transcription","volume":"389","author":"Grunstein","year":"1997","journal-title":"Nature"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/nrg3173","article-title":"Histone methylation: a dynamic mark in health, disease and inheritance","volume":"13","author":"Greer","year":"2012","journal-title":"Nat Rev Genet"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2012.00026","article-title":"Histone ubiquitination and deubiquitination in transcription, DNA damage response, and cancer","volume":"2","author":"Cao","year":"2012","journal-title":"Front Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10048","article-title":"The multifaceted role of lysine acetylation in cancer: prognostic biomarker and therapeutic target","volume":"7","author":"Di Martile","year":"2016","journal-title":"Oncotarget"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18071414","article-title":"Histone Deacetylase Inhibitors as Anticancer Drugs","volume":"18","author":"Eckschlager","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2011.10.009","article-title":"Roles of ubiquitin signaling in transcription regulation","volume":"24","author":"Hammond-Martel","year":"2012","journal-title":"Cell Signal"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/ng.855","article-title":"The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma","volume":"43","author":"Bott","year":"2011","journal-title":"Nat Genet"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2012.02223.x","article-title":"Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma","volume":"103","author":"Yoshikawa","year":"2012","journal-title":"Cancer Sci"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/nature08966","article-title":"Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB","volume":"465","author":"Scheuermann","year":"2010","journal-title":"Nature"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a026575","article-title":"Role of the Polycomb Repressive Complex 2 (PRC2) in Transcriptional Regulation and Cancer","volume":"6","author":"Laugesen","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B52","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1158\/1078-0432.CCR-11-0962","article-title":"Polycomb repressor complex-2 is a novel target for mesothelioma therapy","volume":"18","author":"Kemp","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70056-2","article-title":"Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial","volume":"16","author":"Krug","year":"2015","journal-title":"Lancet Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/nrm.2017.26","article-title":"Mechanisms of action and regulation of ATP-dependent chromatin-remodelling complexes","volume":"18","author":"Clapier","year":"2017","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.4161\/nucl.26654","article-title":"The SWI\/SNF tumor suppressor complex: Regulation of promoter nucleosomes and beyond","volume":"4","author":"Lu","year":"2013","journal-title":"Nucleus"},{"key":"B56","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/ng.2628","article-title":"Proteomic and bioinformatic analysis of mammalian SWI\/SNF complexes identifies extensive roles in human malignancy","volume":"45","author":"Kadoch","year":"2013","journal-title":"Nat Genet"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a026930","article-title":"The Many Roles of BAF (mSWI\/SNF) and PBAF Complexes in Cancer","volume":"6","author":"Hodges","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.febslet.2010.11.024","article-title":"Synthetic lethality: general principles, utility and detection using genetic screens in human cells","volume":"585","author":"Nijman","year":"2011","journal-title":"FEBS Lett"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3480","article-title":"ARID1B is a specific vulnerability in ARID1A-mutant cancers","volume":"20","author":"Helming","year":"2014","journal-title":"Nat Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2018.07.005","article-title":"ARID1A mutant ovarian clear cell carcinoma: A clear target for synthetic lethal strategies","volume":"1870","author":"Caumanns","year":"2018","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/nrg3074","article-title":"Non-coding RNAs in human disease","volume":"12","author":"Esteller","year":"2011","journal-title":"Nat Rev Genet"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncrna.2018.08.001","article-title":"Relations between approved platinum drugs and non-coding RNAs in mesothelioma","volume":"3","author":"Biersack","year":"2018","journal-title":"Noncoding RNA Res"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.05.024","article-title":"Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma","volume":"12","author":"Kao","year":"2017","journal-title":"J Thorac Oncol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30621-6","article-title":"Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study","volume":"18","author":"van Zandwijk","year":"2017","journal-title":"Lancet Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"B66","unstructured":"National Comprehensive Cancer NetworkNCCN malignant pleural mesothelioma guidelines (version 2. 2019)2019"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2017.09.050","article-title":"PD-1 pathway and its clinical application: A 20year journey after discovery of the complete human PD-1 gene","volume":"638","author":"Berger","year":"2018","journal-title":"Gene"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000177","article-title":"B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis","volume":"9","author":"Mansfield","year":"2014","journal-title":"J Thorac Oncol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"e0121071","DOI":"10.1371\/journal.pone.0121071","article-title":"Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)","volume":"10","author":"Cedres","year":"2015","journal-title":"PloS One"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-019-0613-x","article-title":"Use of Immune Checkpoint Inhibitors in Mesothelioma","volume":"20","author":"Forde","year":"2019","journal-title":"Curr Treat Options Oncol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.05.038","article-title":"Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma","volume":"13","author":"Quispel-Janssen","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0103","article-title":"Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT)","volume":"25","author":"Okada","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(18)30151-6","article-title":"Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study","volume":"6","author":"Calabro","year":"2018","journal-title":"Lancet Respir Med"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel","year":"2019","journal-title":"Lancet Oncol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(18)30420-X","article-title":"Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial","volume":"7","author":"Disselhorst","year":"2019","journal-title":"Lancet Respir Med"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30462-9","article-title":"Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in","volume":"21","author":"Nowak","year":"2020","journal-title":"Lancet Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2020.554570\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,10]],"date-time":"2021-01-10T14:17:45Z","timestamp":1610288265000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2020.554570\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,14]]},"references-count":78,"alternative-id":["10.3389\/fonc.2020.554570"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.554570","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,14]]},"article-number":"554570"}}